{"id":57749,"date":"2024-07-30T00:04:46","date_gmt":"2024-07-30T00:04:46","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/07\/30\/nyxoah-to-release-second-quarter-and-first-half-2024-financial-results-on-august-6-2024\/"},"modified":"2024-07-30T00:04:46","modified_gmt":"2024-07-30T00:04:46","slug":"nyxoah-to-release-second-quarter-and-first-half-2024-financial-results-on-august-6-2024","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/nyxoah-to-release-second-quarter-and-first-half-2024-financial-results-on-august-6-2024\/","title":{"rendered":"Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024"},"content":{"rendered":"
\n

Nyxoah to Release Second Quarter and First Half 2024 Financial Results <\/strong>on August 6, 2024<\/strong><\/p>\n

Mont-Saint-Guibert, Belgium \u2013 July 29, 2024, 10:30pm CET \/ 4:30pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong> (\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half 2024 on Tuesday, August 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET \/ 4:30pm ET.<\/p>\n

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q2 2024 earnings call webcast<\/a>. For those not planning to ask a question of management, the Company recommends listening via the webcast.<\/p>\n

If you plan to ask a question, please use the following link: Nyxoah\u2019s Q2 2024 earnings call<\/a>. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.<\/p>\n

The archived webcast will be available for replay shortly after the close of the call. <\/p>\n

About Nyxoah<\/strong>
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah\u2019s lead solution is the Genio\u00ae system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.\u00a0<\/p>\n

For more information, please visit http:\/\/www.nyxoah.com\/<\/a>.<\/p>\n

Caution <\/strong>\u2013 CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.<\/p>\n

Forward-looking statements <\/strong>
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio\u00ae system; planned and ongoing clinical studies of the Genio\u00ae system; the potential advantages of the Genio\u00ae system; Nyxoah\u2019s goals with respect to the development, regulatory pathway and potential use of the Genio\u00ae system; the utility of clinical data in potentially obtaining FDA approval of the Genio\u00ae system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.<\/p>\n

Contacts:<\/strong><\/p>\n

Nyxoah<\/strong>
David DeMartino, Chief Strategy Officer
IR@nyxoah.com<\/a><\/p>\n

For Media<\/strong>
Belgium\/France
Backstage Communication \u2013 Gunther De Backer
gunther@backstagecom.be<\/a><\/p>\n

International\/Germany
MC Services \u2013 Anne Hennecke
anne.hennecke@mc-services.eu<\/a><\/p>\n

\n Attachment<\/strong>\n<\/p>\n